Motexafin lutetium in graft coronary artery disease

Kathryn W. Woodburn, Shari Rodriguez, Atsushi Yamaguchi, Motoya Hayase, Robert C. Robbins, David Kessel

Research output: Contribution to journalConference articlepeer-review

1 Scopus citations


Graft coronary artery disease (GCAD) is the chief complication following cardiac transplantation. Presently, there are limited treatment options. Insights into more expedient diagnosis and amelioration, if only partially, of GCAD are fervently sought. The selectivity of Antrin Injection (a motexafin lutetium sensitizer, Lu-Tex) with subsequent photoactivation (far-red light, 700-760 nm) has been evaluated in several preclinical atherosclerosis models. The inhibitory effect of Lu-Tex induced photosensitization was demonstrated with human bypass coronary smooth muscle cells (SMCs). The biodistribution of Lu-Tex was evaluated in a rat model of heterotopic cardiac allografts 60 days following transplantation. Lu-Tex was retained in the cardiac allograft, exhibiting a five-fold increase in retention between the allograft and native heart. These findings lead us to suggest that further studies are warranted to ascertain the merits of Lu-Tex for the diagnosis and possible attenuation of chronic graft vascular disease.

Original languageEnglish (US)
Pages (from-to)40-44
Number of pages5
JournalProceedings of SPIE - The International Society for Optical Engineering
StatePublished - 2000
Externally publishedYes
EventOptical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX - San Jose, CA, USA
Duration: Jan 22 2000Jan 23 2000

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Condensed Matter Physics
  • Computer Science Applications
  • Applied Mathematics
  • Electrical and Electronic Engineering


Dive into the research topics of 'Motexafin lutetium in graft coronary artery disease'. Together they form a unique fingerprint.

Cite this